Biotech Values

[poorgradstudent]

MYOK:

They're basically doing a version of what CYTK did, but this time they're trying to lower work done by the heart (which I prefer) rather than increase it (as CYTK did).

Worrying thing is that there is lots of overlap between the CYTK and MYOK people, so perhaps some intellectual recycling is going on. The freshest perspective is likely the Seidmans who accrue much of the genetic background data for the inherited cardiomyopathies. Problem with these cardiomyopathies is that many of them impact proteins that don't have catalytic activity, and are therefore not readily drug-able.

I'm interested in this field but see no reason personally to dive into MYOK right now.